
ICER’s Development and Use of RWE: 5 Areas for Concern
The pervasiveness of real-world data (RWD) and the need to understand outcomes in clinical practice have galvanized the ubiquity and utility of real-world evidence (RWE). Especially within the life sciences industry, RWE is increasingly leveraged by research and development, epidemiology, outcomes research, and commercial groups across an asset’s[…]

Top 3 Questions Raised by ICER’s Proposed Changes to its Value Assessment Framework
Just 2 weeks ago, the Institute for Clinical and Economic Review (ICER) proposed changes to its 2017-2019 Value Assessment Framework, which guides the analytic structure of the primary domains of their framework. These 4 domains include comparative clinical effectiveness, long-term cost-effectiveness (CE), potential other benefits or disadvantages[…]

97% of Evaluated Drugs are Overpriced, According to ICER
2018 was not a good year for biopharma manufacturers, based on the Institute for Clinical and Economic Review’s (ICER) evaluation of interventions across various disease areas. Seemingly every month, ICER generated negative press for the biopharma industry. Headlines read:

Do Research Groups Align on the Value of an Intervention? A Prelude to our ISPOR Barcelona Presentation
Do Research Groups Align on the Value of an Intervention? A Prelude to our ISPOR Barcelona Presentation By Matthew Sussman

ICER Versus NICE: Who Cares About Value-Based Pricing Assessments?
This is my last post in an ICER versus NICE series that examines how ICER’s and NICE’s methodologies for implementing cost-effectiveness (CE) analyses differ. My last post explored how differences in the use of a fixed CE threshold and the application of a narrower CE threshold range may lead to different intervention recommendations. In this[…]

Do Fixed Cost-Effectiveness Thresholds or CE Threshold Magnitudes Matter?
In my last post, I highlighted three subtle differences between ICER’s and NICE’s methodologies when conducting cost-effectiveness (CE) analyses. These differences, if overlooked, could actually lead to very different recommendations for coverage, reimbursement, and pricing. Two of these important differences revolve around CE thresholds,[…]

ICER vs. NICE: Three Key Differences in Approach and Appraisal
Back in December, I recapped an issues panel titled, “Should ICER be NICE (or Not)?” from ISPOR’s 20th Annual European Congress, which sought to compare the use of ICER’s value assessment framework versus NICE’s guidelines when conducting and interpreting cost-effectiveness (CE) analyses. In that post, I summarized the ideas expressed during the[…]

ICER Versus NICE: The Verdict From Our ISPOR Glasgow Issue Panel
A smashing success! ISPOR hosted its 20th Annual European Congress in Glasgow, Scotland last month, boasting nearly 5,000 attendees and satisfying our deepest sweet tooth cravings thanks to the lunch menu’s endless supply of teacake biscuits, caramel wafers, caramel shortbread, and IRN Bru. In addition, the conference hosted three well-attended[…]

Should ICER Be NICE (or Not)?: A Prelude to Our ISPOR Glasgow Issue Panel
ISPOR’s 20th Annual European Congress in Glasgow is fast approaching, with the first plenary session scheduled for this Monday, November 6th. I will be attending as part of BHE’s team and am looking forward to the plenary sessions discussing the evolution of value in healthcare, including the increase in value-based care initiatives, the future of[…]

What You Should Know When Considering ICER’s Value Assessment Framework
Over the past several months, our Modeling & Evidence team has been busy tracking the Institute for Clinical and Economic Review’s (ICER) movements. In early February 2017, ICER released a revised Value Assessment Framework, the conceptual framework for guiding their evaluations of clinical and cost-effectiveness. After a three month open-comment[…]